YL217

YL217 is a next-generation antibody-drug conjugate (ADC) developed by Suzhou Medilink Therapeutics. It specifically targets cadherin-17 protein (CDH17), which is overexpressed in several gastrointestinal cancers, including gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. The ADC consists of three components: a recombinant humanized IgG1 monoclonal antibody targeting CDH17 (YL217-mAb), a topoisomerase I inhibitor payload (YL0010014), and an enzymatically cleavable methylsulfonyl pyrimidine tripeptide linker. Preclinical studies have shown that YL217 effectively suppresses tumor growth in models of human colorectal and gastric cancers. The drug is currently in Phase 1 clinical trials for advanced solid tumors with a focus on gastrointestinal neoplasms.